
Looking for a trend day.
"June 5 (Reuters) - A drug delivery system developed by Delcath Systems Inc (DCTH.O) helped melanoma patients whose cancer had spread to their liver live much longer than patients treated with best available care.
The company, which announced in April that the 93-patient trial was successful, will present the detailed results later on Saturday at a meeting of the American Society of Clinical Oncology in Chicago.
A preliminary summary provided to ASCO earlier showed that patients treated with Delcath's PHP System lived for an average of 245 days before dying or having their cancer get worse. Patients treated with standard drugs survived for an average of 49 days before they died or their tumor growth restarted.
Delcath's system is designed to deliver high doses of the chemotherapy drug melphalan directly to the liver, through the hepatic artery. The drug is very toxic, but not for normal cells in the liver.
The system aims to minimize side effects by filtering the drug out of the blood stream as it leaves the liver, but some of the drug does leak out.
As a result, the major side effect seen in the trial was bone marrow suppression.
Delcath has begun a rolling application for its PHP system at the U.S. Food and Drug Administration and expects to complete the package later this year.
The company has estimated peak annual U.S. sales of $745 million if the system is approved for use in melanoma patients whose cancer has spread to the liver. Use in primary liver cancer as well as metastases from other types of cancer could put the sales potential at $5.6 billion. "
The story just keeps getting better and better.(LONG DCTH since $4's) Congrats to those of you who are still long DCTH with me.






FUJIAN, China--(BUSINESS WIRE)--China MediaExpress Holdings, Inc. (NYSE Amex: CCME) (“CME” or “Company”), China’s largest television advertising operator on inter-city and airport express buses, today announced that its common stock has been approved for listing on the NASDAQ Global Select Market.
Effective as of the close of trading on June 2, 2010, the Company’s common stock will cease trading on NYSE AMEX. Upon the opening of trading on June 3, 2010, the Company's shares will commence trading on NASDAQ Global Select Market, under the same ticker symbol "CCME".
Mr. Zheng Cheng, CME’s Founder and CEO, noted, “We believe that NASDAQ represents the best fit for our Company and our shareholders. NASDAQ's market maker structure should lead to increased liquidity, an expansion in our shareholder base and, ultimately, to increased shareholder value. In addition it will provide our investors with the best prices and the fastest execution. As the world's largest electronic stock market, NASDAQ promotes innovation and attracts leading growth companies from a diverse group of sectors. CME is one of the very few Chinese companies to qualify for the NASDAQ Global Select Market, which has the highest initial listing standards of any exchange in the world. Out of 136 China-based companies listed on NASDAQ, only 26 companies such as Baidu, CTrip.com International, Shanda Interactive Entertainment and NetEase.com, fulfill NASDAQ Global Select Market requirements. Within only seven months since CME became a public company in October 2009, we have qualified and are making the decision to move to the NASDAQ Global Select Market. This achievement is an important milestone for our Company and we look to the future with confidence.”
Long and Strong!